ASCRS 2024: An update from ViaLase on its technology for a nonincisional approach to treating glaucoma.
Rick Lewis, chief medical officer of ViaLase, describes the company’s nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.